Celularity Inc — Major Shareholding Notification 2021

Jul 23, 2021

SC 13G 1 tm2123087d2_sc13g.htm SC 13G

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ___)*

CELULARITY INC.

Field: Rule-Page

Field: /Rule-Page

(Name of Issuer)

Class A Common Stock, $0.0001 par value

Field: Rule-Page

Field: /Rule-Page

(Title of Class of Securities)

151190105
(CUSIP Number)

July 16, 2021
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)

• The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1; Options: NewSection

Field: /Page

Page 2 of 6 Pages

CUSIP No. 151190105

1	Names of Reporting Persons Sorrento Therapeutics, Inc.
2	Check the Appropriate Box if
a Member of a Group (See Instructions) (a) ¨ (b) ¨
3	SEC
Use Only
4	Citizenship or Place
of Organization Delaware

| number
of shares beneficially owned by each reporting person with | Sole
Voting Power 20,422,124 |
| --- | --- |
| 6 | Shared Voting Power 0 |
| 7 | S ole
Dispositive Power 20,422,124 |
| 8 | Shared
Dispositive Power 0 |

| 9 | Aggregate
Amount Beneficially Owned by Each Reporting Person 20,422,124 |
| --- | --- |
| 10 | Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) |
| 11 | Percent
of Class Represented by Amount in Row (9) 16.7% (1) |
| 12 | Type
of Reporting Person (See Instructions) CO |

Field: Rule-Page

Field: /Rule-Page

1 Percentage based on 122,487,170 shares of the Issuer’s Class A Common Stock outstanding as of July 16, 2021, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 22, 2021.

Field: Page; Sequence: 2

Field: /Page

Page 3 of 6 Pages

Item 1.

(a) Name of Issuer

Celularity Inc.

(b) Address of Issuer’s Principal Executive Offices

170 Park Avenue
Florham Park, NJ 07932

Item 2.

(a)
Sorrento Therapeutics, Inc. (the “Reporting
Person”)

(b)
4955 Directors Place
San Diego, CA 92121
USA

(c)
The Reporting Person is a corporation organized under the
laws of the State of Delaware.

(d)
Class A Common Stock, $0.0001 par
value

(e)
151190105

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

Field: Page; Sequence: 3

Field: /Page

Page 4 of 6 Pages

(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____.

Item 4. Ownership.

(a) Amount beneficially owned:

20,422,124

(b) Percent of class:

16.7%*

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

20,422,124

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

20,422,124

(iv) Shared power to dispose or to direct the disposition of:

0

• Percentage based on 122,487,170 shares of the Issuer’s Class A Common Stock outstanding as of July 16, 2021, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2021.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Henry Ji, Ph.D., the President and Chief Executive Officer of the Reporting Person, may be deemed to have voting and dispositive power over the shares held by the Reporting Person. Dr. Ji disclaims beneficial ownership with respect to such shares except to the extent of his pecuniary interest therein, if any.

Field: Page; Sequence: 4

Field: /Page

Page 5 of 6 Pages

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Field: Page; Sequence: 5

Field: /Page

Page 6 of 6 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 23, 2021

SORRENTO THERAPEUTICS, INC.

By:
Name: Henry Ji, Ph.D.
Title: President and Chief Executive Officer

Field: Page; Sequence: 6; Options: Last

Field: /Page